BCI Technology for Paralysis

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Synaptrix Labs Inc.

No Placebo Group

Trial Summary

What is the purpose of this trial?

Neuralis is an innovative assistive technology designed for individuals with severe neuromuscular conditions, enabling wheelchair control through EEG signals. This study aims to assess the safety, feasibility, and efficacy of Neuralis in restoring mobility and independence. The device is a discreet EEG headset which specializes in decoding signals from visual cortex, allowing users to initiate precise wheelchair movements through focused attention. This research seeks to demonstrate Neuralis' potential in revolutionizing assistive technology by offering a non-invasive, user-friendly solution for individuals facing motor impairments, ultimately enhancing their quality of life.

Eligibility Criteria

This trial is for individuals with severe paralysis due to conditions like Multiple Sclerosis, Spinal Cord Injury, or ALS. Participants must be able to attend all tests, give consent, speak English fluently, and have a study partner. It's not suitable for those who can't use the device properly.

Inclusion Criteria

You are suitable for using the device.

I have severe weakness in all four limbs.

You are able to agree to participate in the study.

Treatment Details

Interventions

• Neuralis (Brain-Computer Interface)

Trial Overview The EMPOWER study is testing Neuralis, a non-invasive brain-computer interface (BCI) that allows people with paralysis to control their wheelchairs using EEG signals from their visual cortex by focusing their attention.

Participant Groups

Group I: Patient Group / Arm Experimental Treatment 1 Intervention

Use of non-invasive EEG headband device

Who Is Running the Clinical Trial?

Synaptrix Labs Inc.

Lead Sponsor

Trials

1

Recruited

6+